Abivax SA (NASDAQ:ABVX) stock is up on Thursday, even as the company’s shares plunged following the release of trial data.
On Tuesday, the French biotech released data from its Phase 3 ABTECT maintenance trial evaluating obefazimod for ulcerative colitis.
The trial showed significant efficacy, with remission rates exceeding 50% for both doses tested, although concerns about reported cancer cases may weigh on investor sentiment following the trial results.
ABVX Catalyst: Phase 3 Obefazimod Data In Ulcerative Colitis
The Phase 3 trial enrolled 580 patients and demonstrated that both 25 mg and 50 mg doses of obefazimod met the FDA’s primary endpoint of clinical remission, achieving remission rates of 50.8% and 51.3%, respectively.
However, the reported cases of cancer during the study, including prostate and breast cancer, have raised concerns among investors, prompting analysts to caution that these safety signals could impact the stock’s performance.
ABVX Technical Analysis: Trend, Moving Averages And Momentum
Abivax’s stock has seen a remarkable 12-month performance, soaring by 1018.49%. Currently, it is trading significantly below its moving averages, with the price at $91.50 being approximately 22.3% below the 20-day simple moving average (SMA) of $118.94 and 15.8% below the 200-day SMA of $109.69.
The moving average convergence divergence (MACD) is below its signal line, indicating that momentum is fading, suggesting that the stock may struggle to maintain upward pressure unless it can reclaim that baseline.
- Key Resistance: $98.50 — a nearby level where rebounds can stall.
- Key Support: $87.50 — a nearby level where buyers previously stepped in.
Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $133.14. Recent analyst moves include:
- Truist Securities: Buy (Lowers Target to $135.00) (June 2)
- Jefferies: Downgraded to Hold (Lowers Target to $90.00) (June 2)
- Morgan Stanley: Overweight (Lowers Target to $132.00) (June 2)
ABVX Stock Price Activity: Abivax shares were up 3.46% at $93.27 at the time of publication on Thursday, according to Benzinga Pro data.
Image via Shutterstock
